--- title: "Hong Kong Equities Flash Mixed Signals as Airlines Brace for Losses, Biotech Advances" type: "News" locale: "en" url: "https://longbridge.com/en/news/293448947.md" description: "A diverse slate of Hong Kong-listed firms is highlighting a fragmented market in mid-2026. While China Eastern Airlines faces a massive interim loss due to fuel costs, biotech and industrial firms are accelerating strategic expansions." datetime: "2026-07-22T09:18:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293448947.md) - [en](https://longbridge.com/en/news/293448947.md) - [zh-HK](https://longbridge.com/zh-HK/news/293448947.md) generator: "portal-rs" --- # Hong Kong Equities Flash Mixed Signals as Airlines Brace for Losses, Biotech Advances A slew of Hong Kong-listed companies spanning aviation, biotechnology, and heavy machinery are charting diverging paths in mid-2026, underscored by sharp profit warnings, aggressive share buybacks, and steady clinical advancements, according to recent corporate filings and market data. ### China Eastern Airlines **中国东方航空股份 (0670.HK)** is bracing for significant headwinds. The company issued a profit warning for the first half of 2026, forecasting net losses up to **RMB 2.4 billion**. The widening loss is largely driven by a spike in aviation fuel prices, according to the airline, reversing the **RMB 1.63 billion** profit recorded in the first quarter. To buffer market sentiment, the carrier recently repurchased A-shares worth **RMB 30 million**. ### COSCO Shipping Development **中远海发 (2866.HK)** is accelerating its asset expansion, announcing the purchase of **24 dry bulk vessels** in late June to bolster its industry synergy. For Q1 2026, the company posted a **10.49%** increase in revenue to **RMB 5.98 billion**, although net income attributable to shareholders slipped **14.01%**, reflecting shifting margins in its container operations. ### First Tractor Buoyed by robust export data for heavy machinery, **第一拖拉机股份 (0038.HK)** is moving to stabilize its valuation. The company is seeking shareholder approval to buy back up to **10%** of its issued H-shares. Meanwhile, FIL Limited increased its stake in the firm to **7.00%** following a recent market purchase valued at roughly **HKD 1.39 million**. ### SinoHytec The hydrogen fuel cell sector remains mired in early-stage commercialization hurdles. **亿华通 (2402.HK)** disclosed that its subsidiary is suing a partner for **RMB 162 million** in unpaid contracts. Despite revenue surging **58.40%** in Q1 2026, the firm remains unprofitable amid slow cash collection and intense price competition. ### Junshi Biosciences On the biotech front, **君实生物 (1877.HK)** is steadily advancing its pipeline. The company's supplemental new drug application for its anti-PD-1 monoclonal antibody in resectable non-small cell lung cancer was accepted in July. The firm also inked a commercialization partnership for an IL-17A antibody earlier this month. ### Livzon Pharmaceutical Navigating a management transition in 2026, **丽珠医药 (1513.HK)** recently completed the first patient dosing in a Phase I clinical trial for its new injection microspheres. However, its core operations face pressure from raw material price volatility, prompting the new leadership to seek fresh growth catalysts. ### Cutia Therapeutics **科笛-B (2487.HK)** secured a major regulatory milestone with the approval of its topical anesthetic cream for dermatological surgeries. This marks a critical step in commercializing its epidermal anesthesia portfolio. ### Jufutang Bio Small-cap biotech **菊福堂生物 (8217.HK)** posted a turnaround, reporting a net profit of **HKD 23.3 million** for the fiscal year ended March 2026. The profitability was largely driven by **HKD 27 million** in fair value gains on financial assets. ### Market Laggards In the broader market, traditional drugmakers like **山东新华制药股份 (0719.HK)** and niche quantitative plays like **XI 二南策略-U (9399.HK)** are navigating a tepid liquidity environment. Market watchers indicate that the valuation gap between cash-generating industrials and speculative tech assets is poised to widen as Q3 unfolds. *This article does not constitute investment advice.* ### Related Stocks - [02866.HK](https://longbridge.com/en/quote/02866.HK.md) - [02402.HK](https://longbridge.com/en/quote/02402.HK.md) - [01877.HK](https://longbridge.com/en/quote/01877.HK.md) - [01513.HK](https://longbridge.com/en/quote/01513.HK.md) - [02487.HK](https://longbridge.com/en/quote/02487.HK.md) - [08217.HK](https://longbridge.com/en/quote/08217.HK.md) ## Related News & Research - [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md) - [COSCO Shipping Development invests RMB 4.79 billion in 15 new 87,000-DWT grain vessels](https://longbridge.com/en/news/295916440.md) - [Cosco Shipping Development seeks registration for up to RMB 6 billion corporate bond issuance](https://longbridge.com/en/news/294220451.md) - [China's COSCO Shipping Development Orders 15 Large Bulk Carriers Worth USD1.2 Billion](https://longbridge.com/en/news/294346926.md) - [Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)](https://longbridge.com/en/news/291476385.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**